MedPath

Roflumilast

These highlights do not include all the information needed to use ROFLUMILAST TABLETS safely and effectively. See full prescribing information for ROFLUMILAST TABLETS. ROFLUMILAST tablets, for oral use Initial U.S. Approval: 2011

Approved
Approval ID

913f1b95-9c46-40d5-a6e9-cff2e5e07eaa

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 30, 2023

Manufacturers
FDA

American Health Packaging

DUNS: 929561009

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Roflumilast

PRODUCT DETAILS

NDC Product Code60687-786
Application NumberANDA208213
Marketing CategoryC73584
Route of AdministrationORAL
Effective DateOctober 30, 2023
Generic NameRoflumilast

INGREDIENTS (5)

SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT
ROFLUMILASTActive
Quantity: 500 ug in 1 1
Code: 0P6C6ZOP5U
Classification: ACTIB
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
MICROCRYSTALLINE CELLULOSE 102Inactive
Code: PNR0YF693Y
Classification: IACT
© Copyright 2025. All Rights Reserved by MedPath
Roflumilast - FDA Approval | MedPath